Predictive Oncology Says it’s making Significant Progress with FluGen
DENVER, Colo., May 01, 2024 (247marketnews.com)- Predictive Oncology Inc. (NASDAQ:POAI) is developing a flu vaccine for the United States Department of Defense (DoD), in collaboration with FluGen.
“Predictive Oncology will play a critical role in helping to make our M2SR flu vaccine more stable and sustainable as we advance our clinical trials,” claimed Paul Radspinner, President & Chief Executive Officer of FluGen. “The project looks to hold tremendous promise.”
“We are excited to advance these efforts for an intranasal flu vaccine that will be unlike any other on the market,” sad Larry DeLucas, Senior Vice President of Biologics at Predictive Oncology. “Utilizing our exceptional technology and supported by our team of leading scientists, this work will allow FluGen to continue its clinical trials with greater potential to bring a more advanced and stable flu vaccine to patients.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (POAI)
- Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
- UPDATE – Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
- 24/7 Market News Snapshot 22 May, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)
- Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
- 24/7 Market News Snapshot 22 May, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)